Movano Health Explores Sale, Secures $1B Equity Facility Amid 26% Stock Spike

Movano Inc.: Company Overview

Movano Inc. (NASDAQ: MOVE), operating as Movano Health, was founded in 2018 and is headquartered in Pleasanton, California. The company develops medical-grade consumer wearables designed to capture and translate vital health metrics into personalized insights. Its initial offering includes the Evie Ring, a wearable designed for women that tracks metrics such as resting heart rate, heart rate variability, blood oxygen saturation, respiration rate, skin temperature variability, menstrual cycle indicators, and activity profiles.

Corporate Structure and Leadership

According to its LinkedIn profile, Movano Health employs between 11 and 50 people. The executive team combines expertise across medical devices, wireless technologies, regulatory affairs, marketing, and finance:

• A former Medtronic executive who focused on continuous glucose monitoring innovations serves as Chief Technology Officer.
• An MIT-educated RF specialist, inventor of over 200 patents, co-leads engineering efforts.
• A Wall Street professional with 24 years in portfolio management and equity research oversees corporate strategy and financial planning.
• Marketing and operations are guided by leaders with experience at organizations such as Twentieth Century Fox, Hydrow, Bose Health, and Philips.
• Regulatory and clinical oversight is managed by an executive with over 30 years of experience in securing FDA clearances for medical devices.

Wearable Health by Angelina Sarycheva

Recent Developments and News

On May 16, 2025, Movano Health’s Board of Directors announced it had engaged Aquilo Partners and K&L Gates LLP to explore strategic alternatives, including a potential sale or merger, to maximize shareholder value. The company also indicated it would not file its Form 10-Q for the quarter ended March 31, 2025, on time due to resource constraints.

On November 10, 2025, Movano filed a Form 425 prospectus and communications relating to a business combination. The disclosure detailed a $3.0 million equity raise via a Series A Subscription Agreement, a $37.1 million private placement for Corvex Inc., and a $1.0 billion equity facility with Chardan Capital Markets LLC. The filing also outlined plans to amend Movano’s charter, convene a special stockholder meeting to approve share issuances, and adopt new equity incentive plans.

On that same day, Movano’s share price closed at $6.04 on the NASDAQ, reflecting a 26.62 percent increase on a volume of 617,037 shares.

Financial and Strategic Analysis

For the twelve months ending July 11, 2025, Movano reported revenue of $0.47 million and a net loss of $20.22 million, resulting in a negative earnings per share of $27.70. Total cash on hand stood at $2.11 million, with a debt-to-equity ratio of 37.45 percent. The $1.0 billion equity facility provides additional funding capacity, subject to specific terms.

The strategic process initiated on May 16 aims to evaluate potential mergers or sales that could complement Movano’s wearable health technology platform. The equity transactions outlined in the November 10 Form 425 strengthen the company’s liquidity posture while detailing ownership adjustments and governance updates pending stockholder approval.

Market Position and Industry Context

Movano operates within the wearable medical-device segment, which includes competitors such as Oura, Fitbit, and Apple Watch. The company differentiates itself by focusing on non-invasive, cuffless monitoring of blood pressure and glucose and prioritizing women’s health metrics in the Evie Ring. Partnerships with researchers and obtaining FDA clearance for its EvieMED Smart Ring align with its goal to integrate consumer wearables and clinical-grade data. As healthcare providers and consumers increasingly seek continuous, reliable biometric information, Movano’s targeted devices address a specific niche within a broader wearables market projected to grow in the coming decade.

tl;dr

On May 16, 2025, Movano Health’s board initiated a strategic-alternatives review and disclosed a delayed Q1 2025 10-Q filing. On November 10, 2025, the company filed a Form 425 that outlined a $3 million Series A raise, a $1 billion equity facility, and governance changes ahead of a proposed business combination. Shares increased by 26.62 percent to $6.04. Future developments depend on stockholder votes and the outcome of the strategic-alternatives process.